Research programme: 5T4xCD3 bispecific T-cell engagers - AbCellera
Latest Information Update: 17 May 2024
At a glance
- Originator Abcellera
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 11 Apr 2024 Research programme: 5T4xCD3 bispecific T-cell engagers - AbCellera is available for licensing as of 11 Apr 2024. https://abcellera.com/partners/ (AbCellera website, April 2024)
- 08 Apr 2024 Early research in Solid tumours in Canada (Parenteral)
- 28 Sep 2023 AbCellera has patent protection with WIPO for Anti-CD3 antibodies and t-cell engager worldwide